From the Journals

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia


 

FROM CANCER MEDICINE

Risk factors for keratinocyte carcinomas, primarily pigment traits and sun sensitivity, were associated with the risk of developing non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL) in an analysis of 92,097 women in France.

The presence of “many or very many nevi [moles]” was particularly associated with the risk of CLL among individuals in the E3N cohort, according to a report published online in Cancer Medicine. E3N is a prospective cohort of French women aged 40-65 years at inclusion in 1990. Researchers collected cancer data at baseline and every 2-3 years.

Hazard ratios and 95% confidence intervals for associations between patients pigmentary traits and sun exposure and their risk for CLL/NHL were estimated using Cox models, according to study author Louis-Marie Garcin, MD, of the Université Paris-Saclay, Villejuif, and colleagues.

Common etiology?

Among the 92,097 women included in the study, 622 incident cases of CLL/NHL were observed over a median of 24-years’ follow-up.

The presence of nevi was associated with CLL/NHL risk. The HR for “many or very many nevi” relative to “no nevi” was 1.56. The association with number of nevi was strongest for the risk of CLL, with an HR for “many or very many nevi” of 3.00 vs. 1.32 for NHL. In addition, the researchers found that women whose skin was highly sensitive to sunburn also had a higher risk of CLL (HR, 1.96), while no increased risk of NHL was observed. All HR values were within their respective 95% confidence intervals.

Relevant characteristics that were found to not be associated with added CLL/NHL risk were skin or hair color, number of freckles, and average daily UV dose during spring and summer in the location of residence at birth or at inclusion.

These observations suggest that CLL in particular may share some constitutional risk factors with keratinocyte cancers, according to the researchers.

“We report an association between nevi frequency and CLL/NHL risk, suggesting a partly common genetic etiology of these tumors. Future research should investigate common pathophysiological pathways that could promote the development of both skin carcinoma and CLL/NHL,” the researchers concluded.

The study was sponsored by the French government. The authors stated that they had no conflicts of interest.

mlesney@mdedge.com

SOURCE: Garcin L-M et al. Cancer Med. 2020. doi: 10.1002/cam4.3586 .

Recommended Reading

EMA gives green light to avapritinib for GIST, acalabrutinib for CLL
MDedge Hematology and Oncology
BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients
MDedge Hematology and Oncology
Antihistamines synergistically induce CLL cell death with TK inhibitors
MDedge Hematology and Oncology
Oxidative stress linked to cytogenetic abnormalities in CLL
MDedge Hematology and Oncology
Survey quantifies COVID-19’s impact on oncology
MDedge Hematology and Oncology
Two new protein biomarkers may serve as prognostic indicators for outcomes in CLL
MDedge Hematology and Oncology
Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies
MDedge Hematology and Oncology
ESMO offers new clinical practice guideline for CLL
MDedge Hematology and Oncology
Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL
MDedge Hematology and Oncology
Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients
MDedge Hematology and Oncology